PDCD1 and non-small cell lung carcinoma: Antibodies targeting the PD-1/PD-L1 axis have been approved for treating numerous cancers, including non-small-cell lung cancer, small-cell lung cancer, renal cell carcinoma, head and neck squamous cell carcinoma, urothelial carcinoma, breast cancer, and Hodgkin’s lymphoma [107].